ClinicalTrials.gov
public full text
Public Domain
Mesenchymal Cells From Autologous Bone Marrow, Administered Intravenously in Patients Diagnosed With Multiple Sclerosis
This is a phase I / II for the evaluation of the safety and feasibility of intravenous infusion of mesenchymal cells from autologous bone marrow in patients with Multiple Sclerosis. Intravenous administration of autologous mesenchymal cells of bone marrow is feasible and safe and can be effective in treating patients suffering from multiple sclerosis.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Mesenchymal Stem Cells in Multiple Sclerosis (MSCIMS)#889429
- Mesenchymal Stem Cell Transplantation in MS#1486428
- High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study#1058545
- Evaluation of the Role of Mesenchymal Stem Cells in the Treatment of Graft Versus Host Disease#1103390
- Mesenchymal Stem Cells for Progressive Multiple Sclerosis_Sweden#1183624
Record · ID 1483891
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive